Jason Lettmann, ALX Oncology CEO (Lightstone Ventures)
October 3, 2023 07:34 AM EDTUpdated 11:24 AM
R&D

Up­dat­ed: In turn­around, ALX On­col­o­gy’s CD47 block­er shows ef­fi­ca­cy in gas­tric can­cer tri­al

Lei Lei Wu

News Reporter

Don’t write off CD47 just yet.

ALX On­col­o­gy said that 52% of gas­tric can­cer pa­tients who re­ceived its an­ti-CD47 drug evor­pacept in com­bi­na­tion with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

Drug pack­ag­ing man­u­fac­tur­ers brace for im­pact as EU chem­i­cal ban looms

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times